US clears Pfizer’s biosimilar or Epogen, Procrit
The US Food and Drug Administration has approved Pfizer’s Retacrit, a biosimilar of Amgen’s Epogen and Johnson & Johnson’s Procrit.
Read More
Tag: Epogen
Pfizer’s Epogen/Procrit biosimilar wins US backing
Pfizer’s biosimilar of Amgen’s epoetin alfa (Epogen/Procrit) has won backing in the US for approval across all proposed indications.
Read More
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
